Skip to main content

Home/ Dr. Goodyear/ Group items tagged pharmaceuticals

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Nathan Goodyear

Bioavailability of Curcumin: Problems and Promises - Molecular Pharmaceutics (ACS Publi... - 0 views

pubs.acs.org/...mp700113r

curcumin tumeric

shared by Nathan Goodyear on 07 Jun 16 - No Cached
  • Nathan Goodyear on 07 Jun 16
     
    Just abstract available here, but this article reviews the low bioavailability of curcumin and means to get around the limited bioavailability.
ind swift

Anti Tuberculosis | Orthopedic Therapy | Anti-infective | Pharma Company in India | Dru... - 0 views

www.indswiftltd.com/divisions_&_products.php

medicine manufacturers pharmaceuticals manufacturer anti-diarrhoeal anti-allergics anti-inflammatory Hypolipidaemic drugs anti-ulcer top pharma company in Chandigharh

shared by ind swift on 01 Sep 12 - No Cached
  • ind swift on 01 Sep 12
     
    It is a multispecialty division. Its portfolio covers all therapeutic segments which are available in all other divisions like respiratory inclusive of ENT, chest (anti tuberculosis), dentistry, anti-infective and orthopedic therapies . These medicines are tested for quality and are packed in appropriate packing material.
ind swift

Gynecology Drugs| Pharmaceutical Formulations Development | Indian Drug Manufacturers - 1 views

www.indswiftltd.com/gyno_swift_division.php

DISTONE (IJ) 1X24

shared by ind swift on 14 Aug 12 - No Cached
ind swift liked it
  • ind swift on 14 Aug 12
     
    4 ANAPROCT CAP Each Capsule Contains: Neem (Azadirachta Indica) 25 Mg Suran (Amorphophallus Companulatus) 25 Mg Yashtimadhu (Glycirrhiza Glabra) 25 Mg Haritaki (Terminalia Chebula) 25 Mg Kumarighansatva (Aloe Vera) 50 Mg Mukta Shukti Bhasma(Pearl Oyster) 75 Mg Arishtak (Sapindus Trifoliatus) 75 Mg Saphatika Bhasma (Potash Alum) 100 Mg Daruhaldi Ghansatva(Ext.Berberis Aristata)100 Mg Capsule Anit-Haemorroidal Haemostat 5 ANAPROCT OINTMENT Lidocaine U.S.P.
Nathan Goodyear

Alzheimer's Disease: The Pros and Cons of Pharmaceutical, Nutritional, Botanical, and S... - 0 views

www.altmedrev.com/...223.pdf

BDNF Huperzine-A Alzheimer's disease

shared by Nathan Goodyear on 03 Nov 13 - No Cached
  • Nathan Goodyear on 03 Nov 13
     
    I like the inclusion of western medicine and more "natural" medicine in the biochemical treatment of Alzheimer's disease. Brief review of BDNF.
Nathan Goodyear

The multitude and diversity of environmental carci... [Environ Res. 2007] - PubMed result - 0 views

www.ncbi.nlm.nih.gov/...17692309

environmental carcinogens

shared by Nathan Goodyear on 28 Mar 11 - No Cached
  • Of major concerns are: outdoor air pollution by carbon particles associated with polycyclic aromatic hydrocarbons; indoor air pollution by environmental tobacco smoke, formaldehyde and volatile organic compounds such as benzene and 1,3 butadiene, which may particularly affect children, and food pollution by food additives and by carcinogenic contaminants such as nitrates, pesticides, dioxins and other organochlorines. In addition, carcinogenic metals and metalloids, pharmaceutical medicines and cosmetics may be involved
  • Nathan Goodyear on 28 Mar 11
     
    diversity of environmental carcinogens
Nathan Goodyear

Intravenous Ascorbate as a Tumor Cytotoxic Chemotherapeutic Agent - 0 views

www.seanet.com/...d_hypotheses_1995-v44-p207.htm

vitamin C cancer IV vitamin C ascorbic acid

shared by Nathan Goodyear on 05 Mar 18 - No Cached
  • There is a 10 — 100-fold greater content of catalase in normal cells than in tumor cells
  • induce hydrogen peroxide generation
  • Ascorbic acid and its salts (AA) are preferentially toxic to tumor cells in vitro (6 — 13) and in vivo
  • ...36 more annotations...
  • related to intracellular hydrogen peroxide generation
  • only be obtained by intravenous administration of AA
  • Preferentially kills neoplastic cells
  • Is virtually non-toxic at any dosage
  • Does not suppress the immune system, unlike most chemotherapy agents
  • Increases animal and human resistance to infectious agents by enhancing lymphocyte blastogenesis, enhancing cellular immunity, strengthening the extracellular matrix, and enhancing bactericidal activity of neutrophils and modulation of complement protein
  • Strengthens the structural integrity of the extracellular matrix which is responsible for stromal resistance to malignant invasiveness
  • 1969, researchers at the NCI reported AA was highly toxic to Ehrlich ascites cells in vitro
  • In 1977, Bram et al reported preferential AA toxicity for several malignant melanoma cell lines, including four human-derived lines
  • Noto et al reported that AA plus vitamin K3 had growth inhibiting action against three human tumor cell lines at non-toxic levels
  • Metabolites of AA have also shown antitumor activity in vitro
  • The AA begins to reduce cell proliferation in the tumor cell line at the lowest concentration, 1.76 mg/dl, and is completely cytotoxic to the cells at 7.04 mg/dl
  • the normal cells grew at an enhanced rate at the low dosages (1.76 and 3.52 mg/dl)
  • preferential toxicity of AA for tumor cells. >95% toxicity to human endometrial adenocarcinoma and pancreatic tumor cells (ATCC AN3-CA and MIA PaCa-2) occurred at 20 and 30 mg/dl, respectively.
  • No toxicity or inhibition was demonstrated in the normal, human skin fibroblasts (ATCC CCD 25SK) even at the highest concentration of 50 mg/dl.
  • the use of very high-dose intravenous AA for the treatment of cancer was proposed as early as 1971
  • Cameron and Pauling have published extensive suggestive evidence for prolonged life in terminal cancer patients orally supplemented (with and without initial intravenous AA therapy) with 10 g/day of AA
  • AA, plasma levels during infusion were not monitored,
  • the long-term, oral dosage used in those experiments (10 g/day), while substantial and capable of producing immunostimulatory and extracellular matrix modulation effects, was not high enough to achieve plasma concentrations that are generally cytotoxic to tumor cells in culture
  • This low cytotoxic level of AA is exceedingly rare
  • 5 — 40 mg/dl of AA is required in vitro to kill 100% of tumor cells within 3 days. The 100% kill levels of 30 mg/dl for the endometrial carcinoma cells and 40 mg/dl for the pancreatic carcinoma cells in Figure 2 are typical
  • normal range (95% range) of 0.39-1.13 mg/dl
  • 1 h after beginning his first 8-h infusion of 115 g AA (Merit Pharmaceuticals, Los Angeles, CA), the plasma AA was 3.7 mg/dl and at 5 h was 19 mg/dl. During his fourth 8-h infusion, 8 days later, the 1 h plasma level was 158 mg/dl and 5 h was 185 mg/dl
  • plasma levels of over 100 mg/dl have been maintained in 3 patients for more than 5 h using continuous intravenous infusion
  • In rare instances of patients with widely disseminated and rapidly proliferating tumors, intravenous AA administration (10 — 45 g/day) precipitated widespread tumor hemorrhage and necrosis, resulting in death
  • Although the outcomes were disastrous in these cases, they are similar to the description of tumor-necrosis-factor-induced hemorrhage and necrosis in mice (52) and seem to demonstrate the ability of AA to kill tumor cells in vivo.
  • toxic effects of AA on one normal cell line were observed at 58.36 mg/dl and the lack of side effects in patients maintaining >100 mg/dl plasma levels
  • Although it is very rare, tumor necrosis, hemorrhage, and subsequent death should be the highest priority concern for the safety of intravenous AA for cancer patients.
  • Klenner, who reported no ill effects of dosages as high as 150 g intravenously over a 24-h period
  • Cathcart (55) who describes no ill effects with doses of up to 200 g/d in patients with various pathological conditions
  • following circumstances: renal insufficiency, chronic hemodialysis patients, unusual forms of iron overload, and oxalate stone formers
  • Screening for red cell glucose-6-phosphate dehydrogenase deficiency, which can give rise to hemolysis of red blood cells under oxidative stress (57), should also be performed
  • any cancer therapy should be started at a low dosage to ensure that tumor hemorrhage does not occur.
  • patient is orally supplementing between infusions
  • a scorbutic rebound effect can be avoided with oral supplementation. Because of the possibility of a rebound effect, measurement of plasma levels during the periods between infusions should be performed to ensure that no such effect takes place
  • Every effort should be made to monitor plasma AA levels when a patient discontinues intravenous AA therapy.
  • Nathan Goodyear on 05 Mar 18
     
    Older study, 1995, but shows the long-standing evidence that IVC preferentially is cytotoxic to cancer cells.`
Nathan Goodyear

Anti-inflammatory effects of curcumin are associated with down regulating microRNA-155 ... - 0 views

www.tandfonline.com/...13880209.2017.1297838

curcumin inflammation LPS lipopolysaccharides TNF-alpha IL-6

shared by Nathan Goodyear on 04 Oct 17 - No Cached
  • Nathan Goodyear on 04 Oct 17
     
    Curcumin inhibits LPS induced TNF-alpha and IL-6 production in mouse model.
croservices

CROs to Watch (Top CRO) - 1 views

vial.com/...top-cros-to-watch

Health Healthcare CRO Contract Research Organization CROs Top CRO

shared by croservices on 15 Dec 22 - No Cached
croservices liked it
  • croservices on 15 Dec 22
     
    To bring new therapies to market, pharmaceutical, biotechnology, and medical device companies engage contract research organizations (CROs).
Nathan Goodyear

Pharmaceuticals | Free Full-Text | Chronic Cannabigerol as an Effective Therapeutic for... - 0 views

www.mdpi.com/...1442

cisplatin cannabigerol neuropathy CBG phytocannabinoids

shared by Nathan Goodyear on 20 Apr 24 - No Cached
  • Nathan Goodyear on 20 Apr 24
     
    10 mg/kg in males and 15 mg/kg in females without side effects
‹ Previous 21 - 39 of 39
Showing 20▼ items per page